Navigation Links
Suicide Prevention Organization Launches New Website
Date:10/12/2007

n average every 16 minutes. Suicide is the 3rd leading cause of death among 10-24 year olds and the second leading cause of death for 24-34 year olds. Save responds to more the 1000 internet requests each year and expects a significant increase in inquiries with the release of the new website.

SAVE is committed to the education of the general public about the depressive brain diseases (such as clinical depression and bipolar illness) that can result in suicide if left untreated. By educating the general public about such brain diseases, SAVE strives to remove the stigma associated with these diseases. SAVE's prevention and education programs include a school-based program educating staff, parents and students, community and professional presentation through a volunteer speaker's bureau, professional conference presentations and exhibitions, educational materials distributed internationally, national multi-media public service advertising campaign and community action kits.

For more information on SAVE, go to http://www.save.org or call 952-946-7998.

CONTACT:

Dr. Daniel J. Reidenberg, PsyD, FAPA,

Executive Director

SAVE - Suicide Awareness Voices of Education

952-946-7998 ext. 12

dreidenberg@save.org


'/>"/>
SOURCE Suicide Awareness Voices of Education
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. The big brain in suicides
2. Stress response increases suicide risk
3. Suicide risk in panic disorder
4. Acne Drug linked to suicide attempts
5. A Blood test for suicide risk?
6. Mental illness a key factor in suicide
7. Suicide risk high in 12-17 Age Group
8. Suicide might be inherited
9. Suicide reduced by anti-depressants
10. Twins Less Prone to Suicide Than Others
11. Suicide Prevention Program – Having its Intended Effec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... DIEGO, Dec. 17 CareFusion Corporation (NYSE: ... notified of an unsolicited mini-tender offer by TRC Capital ... of CareFusion common stock, representing approximately 1.8 percent of ... of $23.50 per share is 4.62 percent below the ... 14, 2009, the last full trading day prior to ...
(Date:12/17/2009)... John Howell, CEO of Arrayit ... Corporation (OTC Bulletin Board: ARYC), today formally ... of its microarray-based OvaDx(TM) Pre-Symptomatic ... advancing through late-stage development - the rights ... the Company by Arrayit Corporation. ,, Howell ...
(Date:12/17/2009)... December 17 Researchers from the School ... University in the UK are today,encouraging families ... the,New Year following concerning research* that shows two-thirds ... as a family (68%), with the,Portuguese being the ... to,walk together. , According ...
(Date:12/17/2009)... a revealing portrait of the nearly one-in-three American adults who serve ... ... December 17, 2009 -- The National Alliance on Mental Illness (NAMI) ... which offers a revealing portrait of the nearly one-in-three American adults ... based on interviews with 1,480 caregivers chosen at random and offers ...
(Date:12/17/2009)... the past three years and what has driven these changes ... ... the human capital research firm, will host a webinar titled “The ... hour-long webinar will be broadcast on Wednesday, January 27, 2010 at ... SVP, Consulting Services and Trevor Byrd, Ph.D., a Morehead Consultant, as ...
Breaking Medicine News(10 mins):Health News:CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital 2Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 2Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 3Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 4Health News:The Family Walk - a Dying Tradition Around the World? 2Health News:NAMI Applauds New Report on Caregiving 2Health News:NAMI Applauds New Report on Caregiving 3Health News:Morehead Presents Webinar on "The State of Employee Engagement: A Year in Review" 2
... over 77,000 Votes, St. Jude Children,s Research Hospital(R) Wins ... weeks, St. Jude Children,s Research Hospital(R) tallied 26.6% of ... first-ever Target giving campaign on Facebook(R). Bullseye Gives, ... 25, 2009, invited Facebook users to visit ...
... Creative Therapies to help children with special needsBRADENTON, Fla., ... today announced plans to open a new 9-acre ... in the development of children with special needs. ... Nathanson , the program is thought to be the ...
... be re-evaluated, experts say, , , TUESDAY, May 26 ... better faster, giving acid-suppressing medications to many hospital ... while in the hospital, new research suggests. , ... been shown to prevent serious gastrointestinal problems caused ...
... OVIEDO, Fla., May 26 It,s official. Central Floridians ... Pressure Screenings in a Single Day. The new record 2,075 blood ... on May 23 in Oviedo, FL. In from London was ... verified the record onsite. Country Music star Jake Owen, ...
... ROCHESTER, Minn., May 26 Patients living with ... a positive future. Two review articles and an ... Another Pill," in the current issue of Mayo ... premise."Migraine is a potentially chronic, progressive disease that ...
... Pa., May 26 Pennsylvania is partnering with ... enjoy a healthier and longer life, Secretary of ... Zahorchak announced today.James and Zahorchak visited Albert Gallatin ... to announce two new initiatives aimed at increasing ...
Other Medicine News:Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 2Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 3Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 4Health News:World's First Animatronic Animal Therapy Program Set to Open 2Health News:World's First Animatronic Animal Therapy Program Set to Open 3Health News:Acid-Suppressing Meds May Boost Pneumonia Risks 2Health News:Acid-Suppressing Meds May Boost Pneumonia Risks 3Health News:Mayo Clinic Proceedings: The Evolution of Migraine from Episodic Headache to Chronic Disorder 2Health News:Mayo Clinic Proceedings: The Evolution of Migraine from Episodic Headache to Chronic Disorder 3Health News:Pennsylvania Secretaries of Health, Education Announce New Grant Initiatives to Curb Childhood Obesity, Boost Physical Activity in Schools 2
(Date:12/16/2009)... Dec. 16 TechniScan, Inc. ... a medical device company engaged in the development ... system, announced today that Joe Pepper, PhD, has ... ,, Board Chairman Ken Hungerford commented, "Joe ... devices companies, including GE OEC Medical and U-Systems, ...
(Date:12/16/2009)... -- Naurex Inc., a new clinical stage company ... disorders based on its novel GFPA NMDA receptor ... Phase I clinical trial of its lead compound ... in the study. GLYX-13, a glycine site ... NMDA receptor, is initially being developed as a ...
(Date:12/16/2009)... 16 The Boards of Silence Therapeutics ... to announce the merger of their businesses to ... RNAi (RNA interference). The enlarged company, to ... discovery, development and delivery technologies, a broad internal ... of intellectual property. ,, The Directors believe ...
Breaking Medicine Technology:In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 2Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 4Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 5Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 6ARUP Laboratories Announces New CMO Appointment 50826 1ARUP Laboratories Announces New CMO Appointment 50826 2Despite More Tests Some Arent Getting Results 50822 1Despite More Tests Some Arent Getting Results 50822 2Despite More Tests Some Arent Getting Results 50822 3Antidepressants aid electroconvulsive therapy in treating severe depression 50818 1Antidepressants aid electroconvulsive therapy in treating severe depression 50818 2
... Reported Unlike What Is Commonly Seen In,Insulin Therapy, ... announced results of a new study that further ... detemir,[rDNA origin] injection). Patients with type 2 diabetes ... and achieve improvements,in blood sugar, comparable to dosing ...
... of DG041 as an,effective anti-platelet that does ... 25, 2007 /PRNewswire-FirstCall/ --,deCODE genetics today announced ... Phase II developmental compound for the,prevention of ... IIa and,clinical pharmacology studies presented today build ...
Other Medicine Technology:New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 2New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 3New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 4New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 5Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 2Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 3Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 4Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 5Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 6
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Medicine Products: